Nicotinamide mononucleotide protects against diabetic nephropathy via IL-6/Rab5-mediated crosstalk between proximal tubular epithelial cells and podocytes.

Zha DQ, Gao P, Wu XY

World journal of diabetes1 Oct 2025Cited by 2 (Europe PMC)

PMID41113491PMCIDPMC12531701DOI10.4239/wjd.v16.i10.109782PepBankPUB-41113491

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, NMN reduced podocyte injury.
In plain wordsIn diabetic mice, NMN reduced podocyte injury.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreasePodocyte injury
Study
mousen: not reported in source
streptozotocin-induced diabetic nephropathy
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 8 weeksAs given in this study (mouse).
Source sentences
Summary
NMN treatment of diabetic mice markedly reduced podocyte injury, glomerular hypertrophy, foot-process effacement, and urinary albumin excretion.
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo, DN was induced in mice using streptozotocin, and mice then received NMN, insulin, or both treatments over an 8-week period.
Report a problemFND-4111349101
02AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, NMN reduced glomerular hypertrophy.
In plain wordsIn diabetic mice, NMN reduced enlargement of kidney glomeruli.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseGlomerular hypertrophy
Study
mousen: not reported in source
streptozotocin-induced diabetic nephropathy
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 8 weeksAs given in this study (mouse).
Source sentences
Summary
NMN treatment of diabetic mice markedly reduced podocyte injury, glomerular hypertrophy, foot-process effacement, and urinary albumin excretion.
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo, DN was induced in mice using streptozotocin, and mice then received NMN, insulin, or both treatments over an 8-week period.
Report a problemFND-4111349102
03AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, NMN reduced foot-process effacement.
In plain wordsIn diabetic mice, NMN reduced damage to podocyte foot processes.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseFoot-process effacement
Study
mousen: not reported in source
streptozotocin-induced diabetic nephropathy
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 8 weeksAs given in this study (mouse).
Source sentences
Summary
NMN treatment of diabetic mice markedly reduced podocyte injury, glomerular hypertrophy, foot-process effacement, and urinary albumin excretion.
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo, DN was induced in mice using streptozotocin, and mice then received NMN, insulin, or both treatments over an 8-week period.
Report a problemFND-4111349103
04AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, NMN reduced urinary albumin excretion.
In plain wordsIn diabetic mice, NMN reduced albumin loss in urine.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseUrinary albumin excretion
Study
mousen: not reported in source
streptozotocin-induced diabetic nephropathy
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 8 weeksAs given in this study (mouse).
Source sentences
Summary
NMN treatment of diabetic mice markedly reduced podocyte injury, glomerular hypertrophy, foot-process effacement, and urinary albumin excretion.
1 context sentence(design, population, supporting numbers)
Summary · context
In vivo, DN was induced in mice using streptozotocin, and mice then received NMN, insulin, or both treatments over an 8-week period.
Report a problemFND-4111349104
05LabIn vitro (cells)Mechanism
In PTECs, NMN suppressed epithelial-mesenchymal transition.
In plain wordsIn cells, NMN suppressed the transition of kidney tubular cells toward a mesenchymal state.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreasePTEC EMT
Study
humann: not reported in source
high-glucose PTECs
Outcome group
Receptor activity and mechanism · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Mechanistically, NMN suppressed the EMT and IL-6 secretion by PTECs, inhibited Rab5 activation in podocytes, and prevented nephrin endocytosis, thereby preserving the cytoskeletal integrity and function of podocytes.
1 context sentence(design, population, supporting numbers)
Summary · context
In vitro, human PTECs and murine podocytes were cultured under high-glucose conditions, and IL-6 neutralizing antibodies or NMN treatments were applied.
Report a problemFND-4111349105
06LabIn vitro (cells)Mechanism
In PTECs, NMN suppressed IL-6 secretion.
In plain wordsIn cells, NMN reduced IL-6 release from kidney tubular cells.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreasePTEC IL-6 secretion
Study
humann: not reported in source
high-glucose PTECs
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Mechanistically, NMN suppressed the EMT and IL-6 secretion by PTECs, inhibited Rab5 activation in podocytes, and prevented nephrin endocytosis, thereby preserving the cytoskeletal integrity and function of podocytes.
1 context sentence(design, population, supporting numbers)
Summary · context
In vitro, human PTECs and murine podocytes were cultured under high-glucose conditions, and IL-6 neutralizing antibodies or NMN treatments were applied.
Report a problemFND-4111349106
07LabIn vitro (cells)Mechanism
In podocytes, NMN inhibited Rab5 activation.
In plain wordsIn cells, NMN reduced Rab5 activation in podocytes.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseRab5 activation
Study
mousen: not reported in source
podocytes under high-glucose conditions
Outcome group
Receptor activity and mechanism · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Mechanistically, NMN suppressed the EMT and IL-6 secretion by PTECs, inhibited Rab5 activation in podocytes, and prevented nephrin endocytosis, thereby preserving the cytoskeletal integrity and function of podocytes.
1 context sentence(design, population, supporting numbers)
Summary · context
In vitro, human PTECs and murine podocytes were cultured under high-glucose conditions, and IL-6 neutralizing antibodies or NMN treatments were applied.
Report a problemFND-4111349107
08LabIn vitro (cells)Mechanism
In podocytes, NMN prevented nephrin endocytosis.
In plain wordsIn cells, NMN prevented nephrin uptake into podocytes.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseNephrin endocytosis
Study
mousen: not reported in source
podocytes under high-glucose conditions
Outcome group
Receptor activity and mechanism · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Mechanistically, NMN suppressed the EMT and IL-6 secretion by PTECs, inhibited Rab5 activation in podocytes, and prevented nephrin endocytosis, thereby preserving the cytoskeletal integrity and function of podocytes.
1 context sentence(design, population, supporting numbers)
Summary · context
In vitro, human PTECs and murine podocytes were cultured under high-glucose conditions, and IL-6 neutralizing antibodies or NMN treatments were applied.
Report a problemFND-4111349108
09LabIn vitro (cells)Efficacy outcome
In podocytes, NMN preserved cytoskeletal integrity and function.
In plain wordsIn cells, NMN preserved podocyte internal structure and function.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
Direction not reportedPodocyte cytoskeletal integrity and function
Study
mousen: not reported in source
podocytes under high-glucose conditions
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Mechanistically, NMN suppressed the EMT and IL-6 secretion by PTECs, inhibited Rab5 activation in podocytes, and prevented nephrin endocytosis, thereby preserving the cytoskeletal integrity and function of podocytes.
1 context sentence(design, population, supporting numbers)
Summary · context
In vitro, human PTECs and murine podocytes were cultured under high-glucose conditions, and IL-6 neutralizing antibodies or NMN treatments were applied.
Report a problemFND-4111349109

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.